ChemoCentryx, Inc.
CCXI
CCXI was delisted on the 19th of October, 2022.
1 hedge funds and large institutions have $52 invested in ChemoCentryx, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 212 closing their positions.
100% less funds holding
Funds holding: 217 → 1 (-216)
100% less funds holding in top 10
Funds holding in top 10: 12 → 0 (-12)
100% less capital invested
Capital invested by funds: $3.2B → $52 (-$3.2B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 212
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$311M |
| 2 |
Goldman Sachs
New York
|
-$290M |
| 3 |
BlackRock
New York
|
-$250M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$141M |
| 5 |
State Street
Boston,
Massachusetts
|
-$140M |
CCXI Hedge Fund Activity: Q4 2022 in Review
1 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q4 2022, worth a combined $52 — down 100% from $3.2B a quarter earlier.
Sellers outnumbered buyers: 212 funds closed out of CCXI and 0 opened new positions — a net loss of 212 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $311M sold.
- 1 institutional investor held ChemoCentryx, Inc. (CCXI) as of Q4 2022, down from 217 in Q3 2022.
- Funds reported $52 of ChemoCentryx, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new ChemoCentryx, Inc. positions in Q4 2022 and 212 closed out, a net change of -212 holders.
- The largest ChemoCentryx, Inc. seller in Q4 2022 was Vanguard Group, an estimated $311M sold.
Based on aggregated 13F filings for Q4 2022.